Organization
Taussig Cancer Institute
29 abstracts
Abstract
Metabolomic differences in young-onset versus average-onset colorectal adenocarcinoma.Org: Cleveland Clinic Lerner College of Medicine, Taussig Cancer Institute, Cleveland Clinic Lerner Research Institute,
Abstract
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).Org: Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Université Paris-Sud, Université Paris-Saclay, Netherlands Cancer Institute,
Abstract
NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).Org: Memorial Sloan Kettering Cancer Center, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Washington University School of Medicine in St. Louis, Washington University School of Medicine,
Abstract
Hope drives quality of life in patients with brain metastases, but the hope center remains elusive: An analysis of NRG-CC003.Org: Sharei Zedek Hospital, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Northwestern Medicine Cancer Center Warrenville, Northwestern Medicine Proton Center, Baptist Health South Florida,
Abstract
Therapy-related myeloid neoplasm risk score (TMNRS): A convenient clinical score for TMN risk assessment at presentation in adult patients (pts) with cancer.Org: Department of Hematology and Medical Oncology at Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Roswell Park Comprehensive Cancer Center, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine,
Abstract
Establishing a protocol to increase racial/ethnic minority enrollment on an active radiation oncology randomized clinical trial.Org: Johns Hopkins University School of Medicine, Johns Hopkins Bloomberg School of Public Health, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation,
Abstract
An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Mayo Clinic, Miami Cancer Institute, Baptist Health South Florida, NW Medical Specialties,
Abstract
Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy.Org: Cleveland Clinic Taussig Cancer Instititute, Taussig Cancer Institute, Cleveland Clinic Foundation,
Abstract
Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.Org: Huntsman Cancer Institute at the University of Utah, SWOG Statistics and Data Management Center, Seattle, WA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, University of Kentucky, Lexington, KY,
Abstract
Fostering collaborative care in multiple myeloma: The impact of holistic education on decision-making with antibody and CAR-T platforms.Org: PVI, PeerView Institute for Medical Education, HealthTree Foundation, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Comprehensive assessment of adverse event profiles associated with bispecific T cell engagers in multiple myeloma.Org: 1DATA Consortium, Kansas State University–Olathe, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Predicting fitness for chemotherapy in older adults with metastatic bladder cancer.Org: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Memorial Sloan Kettering Cancer Center,
Abstract
Disparities in multiple myeloma: A global perspective on drug toxicity trends.Org: DATA Consortium, Computational Comparative Medicine, Department of Mathematics, Università degli Studi di Genova, San Martino, Italy, Kansas State University–Olathe, Olathe, KS,
Abstract
Phase I study of BTK inhibitor ibrutinib with temozolomide and radiation in newly-diagnosed glioblastoma (EQUILIBRIUM): Final trial report.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation, Cleveland Clinic Brunswick Urgent Care,
Abstract
Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.Org: Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, UT Southwestern Medical Center, Medical University of South Carolina Hollings Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Stanford University School of Medicine,
Abstract
Identification and management of clonal hematopoiesis of indeterminate potential (CHIP) in cancer survivors: The Cleveland Clinic experience.Org: Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Sylvester Comprehensive Cancer Center, Miami, FL,
Abstract
Post-marketing surveillance safety analysis of patients with CNS malignancies treated with tumor treating fields (TTFields) therapy between 2011–2022.Org: Mayo Clinic Cancer Center, Thomas Jefferson University, New York-Presbyterian/Columbia University Medical Center, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute,
Abstract
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.Org: Clinical Care Options, LLC, Reston, VA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).Org: Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Cleveland Clinic Lerner Research Institute, Cleveland, OH,
Abstract
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).Org: Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York-Presbyterian Hospital, The Tisch Cancer Institute,
Abstract
Neutrophil-to-lymphocyte ratio as a predictor of immune checkpoint inhibitor therapy response in advanced bladder cancer.Org: Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Taussig Cancer Instititute, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Incidence of solid malignancies (SM) among patients with Waldenström macroglobulinemia (WM): Analysis of the SEER database (2000-2019).Org: Roswell Park Comprehensive Cancer Center, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Saint Vincent Hospital Cancer Center Green Bay,
Abstract
Acute lymphocytic leukemia incidence and survivability trends in the United States over the last two decades: SEER data set from 2000-2019.Org: Huntington Beach High School, Leukemia Program, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Impact of COVID-19 pandemic on lung cancer diagnosis in a community hospital.Org: Saint Vincent Hospital Cancer Center Green Bay, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
A novel risk assessment metric for antimyeloma therapies and drug interactions.Org: Kansas State University–Olathe, DATA Consortium, Computational Comparative Medicine, Department of Mathematics, Università degli Studi di Genova, San Martino, Italy, Myeloma Program,
Abstract
A population-level analysis of survival in patients with ALK+ anaplastic large cell lymphoma (ALCL) in the era of novel therapies.Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Department of Translational Hematology and Oncology Research, Lerner Research Institute, Lerner Research Institute,
Abstract
A pilot study to determine the effects of early palliative care integration on patients with newly diagnosed multiple myeloma.Org: Cleveland Clinic Taussig Cancer Instititute, Taussig Cancer Institute,
Abstract
The efficacy of autologous hematopoietic cell transplantation in standard risk multiple myeloma refractory to multiple therapies.Org: Department of Translational Hematology and Oncology Research, Lerner Research Institute, Lerner Research Institute, Cleveland Clinic Taussig Cancer Instititute, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland, OH, Cleveland Clinic Taussig Cancer Center, Cleveland, OH,
Abstract
Association of weight loss with risk of myelodysplastic syndromes (MDS) in adults with obesity: Insights from the SPLENDID cohort.Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Cleveland, OH, Bariatric and Metabolic Institute,